aTyr Pharma (ATYR)
(Delayed Data from NSDQ)
$3.04 USD
-0.08 (-2.56%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $3.02 -0.02 (-0.66%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATYR 3.04 -0.08(-2.56%)
Will ATYR be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ATYR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATYR
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates
Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year?
ATYR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ATYR
Promising Outlook for aTyr Pharma’s Efzofitimod in Pulmonary Sarcoidosis: Buy Rating Affirmed
aTyr Pharma management to meet virtually with Piper Sandler
aTyr Pharma management to meet virtually with Piper Sandler
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and aTyr Pharma (ATYR)